Omaveloxolone for the Treatment of Friedreich Ataxia: Efficacy, Safety, and Future Perspectives

Authors

Saba Naghipour (ORCID: https://orcid.org/0000-0001-6624-5674)
Mirella Dottori (ORCID: https://orcid.org/0000-0003-0598-4195)
Martin Bruce Delatycki (ORCID: https://orcid.org/0000-0002-8769-2569)
Shiang Y. Lim (ORCID: https://orcid.org/0000-0002-0442-3655)
Jarmon G. Lees (ORCID: https://orcid.org/0000-0002-9259-8657)
Amy E. Hulme
Louise A. Corben (ORCID: https://orcid.org/0000-0001-8767-4582)

Institutions

The University of Melbourne (AU)
University of Wollongong (AU)
O'Brien Institute (AU)
Victorian Clinical Genetics Services (AU)
National Heart Centre Singapore (SG)
Murdoch Children's Research Institute (AU)
Monash University (AU)
St Vincents Institute of Medical Research (AU)

Publication Details

Journal: Movement Disorders
Published: 2024-11-19
DOI: https://doi.org/10.1002/mds.30070
Citations: 8
Primary Topic: Genetic Neurodegenerative Diseases
Type: article
Field-Weighted Citation Impact: 2.15

Funders

Friedreich's Ataxia Research Alliance
National Ataxia Foundation
National Health and Medical Research Council

Controls

|||

ALL TIME

JAN

FEB

MAR

APR

MAY

JUN

JUL

AUG

SEP

OCT

article

Omaveloxolone for the Treatment of Friedreich Ataxia: Efficacy, Safety, and Future Perspectives

Saba Naghipour, Mirella Dottori, Martin Bruce Delatycki, Shiang Y. Lim et al.

Nov 19, 2024

8 citations

Movement Disorders

Genetic Neurodegenerative Diseases

2.15

article

Omaveloxolone for the Treatment of Friedreich Ataxia: Efficacy, Safety, and Future Perspectives

Saba Naghipour, Mirella Dottori, Martin Bruce Delatycki, Shiang Y. Lim, Jarmon G. Lees, Amy E. Hulme, Louise A. Corben

November 19, 2024article en

8 citations

Abstract

No abstract available for this paper.

Movement DisordersVol. 40(2)

The University of Melbourne (AU), University of Wollongong (AU), O'Brien Institute (AU), Victorian Clinical Genetics Services (AU), National Heart Centre Singapore (SG), Murdoch Children's Research Institute (AU), Monash University (AU), St Vincents Institute of Medical Research (AU)

Friedreich's Ataxia Research Alliance, National Ataxia Foundation, National Health and Medical Research Council

Openalex Percentile: Top 12%

Genetic Neurodegenerative Diseases

2.15

DOI Source OpenAlex

AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Omaveloxolone for the Treatment of Friedreich Ataxia: Efficacy, Safety, and Future Perspectives — Saba Naghipour, Mirella Dottori, et al. · Movement Disorders (2024) | TGRS Research Map | TGRS